These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1837851)

  • 1. Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients.
    Macdougall IC; Davies ME; Hallett I; Cochlin DL; Hutton RD; Coles GA; Williams JD
    Nephrol Dial Transplant; 1991; 6(11):862-7. PubMed ID: 1837851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemorheology and fistula function in home hemodialysis patients following erythropoietin treatment: a prospective placebo-controlled study.
    Shand BI; Buttimore AL; Hurrell MA; Wells JE; Inkster JA; Bailey RR; Robson RA; Lynn KL
    Nephron; 1993; 64(1):53-7. PubMed ID: 7880205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.
    Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH
    Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin.
    Małyszko JS; Małyszko J; Pawlak K; Pawlak D; Buczko W; Myśliwiec M
    Nephron; 2000 Apr; 84(4):305-11. PubMed ID: 10754406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of subcutaneous administration of recombinant human erythropoietin on plasma protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Yin JA; Li PK; Yuen PM; Lui SF
    Int J Artif Organs; 1992 May; 15(5):264-8. PubMed ID: 1601509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation.
    Jaar B; Denis A; Viron B; Verdy E; Chamma F; Siohan P; Mignon F
    Am J Nephrol; 1997; 17(5):399-405. PubMed ID: 9382155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year experience of very low doses of subcutaneous erythropoietin in continuous ambulatory peritoneal dialysis and its effect on haemostasis.
    Huraib S; Gader AM; al-Momen AK; Abu-Aisha H; al-Wakeel J; Memon NA
    Haemostasis; 1995; 25(6):299-304. PubMed ID: 8586321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disorders of haemostasis in patients undergoing maintenance haemodialysis, with special reference to recurrent arteriovenous fistula thrombosis. Effects of dipyridamole (author's transl)].
    Jacques C; Drueke T; Nedellec J; Kremp O; Gazengel C
    Pathol Biol (Paris); 1976 Dec; 24 Suppl():27-32. PubMed ID: 827731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin and cardiovascular risk.
    Allegra V; Martimbianco L; Mengozzi G; Vasile A
    Blood Purif; 1995; 13(6):301-13. PubMed ID: 8821194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
    de Fijter CW; Popp-Snijders C; Oe LP; Tran DD; van der Meulen J; Donker AJ
    Haematologica; 1995; 80(4):332-4. PubMed ID: 7590502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some aspects of hemostasis in CAPD patients treated with erythropoietin.
    Małyszko J; Suchowierska E; Małyszko JS; Myśliwiec M
    Kidney Blood Press Res; 2002; 25(4):240-4. PubMed ID: 12424426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula.
    Erdem Y; Haznedaroglu IC; Celik I; Yalcin AU; Yasavul U; Turgan C; Caglar S
    Nephrol Dial Transplant; 1996 Jul; 11(7):1299-305. PubMed ID: 8672026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
    Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
    Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients.
    De Marchi S; Cecchin E; Falleti E; Giacomello R; Stel G; Sepiacci G; Bortolotti N; Zanello F; Gonano F; Bartoli E
    J Am Soc Nephrol; 1997 Jul; 8(7):1147-56. PubMed ID: 9219165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in determinants of blood rheology during treatment with haemodialysis and recombinant human erythropoietin.
    Koppensteiner R; Stockenhuber F; Jahn C; Balcke P; Minar E; Ehringer H
    BMJ; 1990 Jun; 300(6740):1626-7. PubMed ID: 2372642
    [No Abstract]   [Full Text] [Related]  

  • 16. [Changes in endothelial vasoactive substances and blood coagulation and fibrinolysis functions under recombinant human erythropoietin therapy in hemodialysis patients].
    Takayama K
    Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):179-88. PubMed ID: 8315881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
    Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
    Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure and heart rate in chronic haemodialysis patients.
    van de Borne P; Tielemans C; Vanherweghem JL; Degaute JP
    Nephrol Dial Transplant; 1992; 7(1):45-9. PubMed ID: 1316580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.